2021 — the year UK biotechs broke investment records
Initial Public Offerings totalled £1,304 million, an increase of 434% from 2020, but more needs to be done to connect the UK's life sciences and finance sectors
Investment in UK biotech and life science companies scored a lifetime high in 2021, according to new data from the BioIndustry Association and Clarivate.
From 1 December 2020 to 30 November 2021, £4.5 billion was raised in public and private financings — £1.7 billon (60%) more than in 2020.
Venture capital made up the lion's share of the total raised (£2,518 million, an increase of 81% from 2020), yet it is the number and scale of Initial Public Offerings (IPOs) that mark out the year as distinctly different to what the UK has previously seen, with a not-so-subtle increase of 434% from 2020 — that's a rise from £244 million in 2020 to £1,304 million.
Oxford Nanopore, for example, topped UK Venture deals for the second year running with a £195 million fundraise prior to their £350 million London IPO, which was the largest amount raised in a listing on the London Stock Exchange by a biotech company.
Another notable company investment was Vaccitech, the Oxford University spin-out commercialising the technology platform behind the Oxford/AstraZeneca COVID-19 vaccine, which raised a large series B round of £118 million prior to their IPO on NASDAQ.
The data also show UK company listings on markets on both sides of the Atlantic, which suggest an ecosystem reaching maturity. Furthermore, the record-breaking levels of venture investment indicates a healthy pipeline of companies coming through.
Steve Bates OBE, Chief Executive of the BIA, said 2021's large fundraises were primarily the result of "welcome" overseas investment. Despite the UK having two world-leading sectors — life sciences and finance — a symbiosis between the two is lacking.
"There is great opportunity to turbo-charge the UK’s biotech and life sciences sector and capture more of its economic value for the UK by building better connections between the UK’s financial institutions and our innovative scaling businesses,” said Bates.
Commenting of the data, George Freeman MP, Minister for Science, Research and Innovation said the UK must complement the overseas investment with "the full financial firepower of the City of London" to encourage more companies to remain in the UK.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance